# Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors

> **NCT02271711** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Recurrent Childhood Medulloblastoma
- Recurrent Ependymoma
- Recurrent Medulloblastoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Natural Killer Cell Therapy

## Key facts

- **NCT ID:** NCT02271711
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-17
- **Primary completion:** 2020-08-28
- **Final completion:** 2020-08-28
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-09-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02271711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02271711, "Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02271711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*